Precision Medicine of Pituitary Adenomas: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Corneliu Toader
,
Nicolaie Dobrin
,
Catalina-Ioana Tataru
,
Razvan-Adrian Covache-Busuioc
,
Bogdan-Gabriel Bratu
,
Luca Andrei Glavan
,
Horia Petre Costin
,
Antonio Daniel Corlatescu
,
David-Ioan Dumitrascu
,
Alexandru Vlad Ciurea

Pituitary adenomas is a type of brain tumor with diverse behaviors and complexities. About half of pituitary adenomas are known to secrete specific hormones, most frequently prolactin, growth hormone, or adrenocorticotropic hormone. Despite being histologically benign, these tumors can cause significant endocrine disturbances, leading to considerable morbidity and potentially shortening lifespan. Due to their pathophysiological endocrine secretion and proximity to critical neural and vascular structures, hormone-secreting pituitary adenomas require comprehensive management.

  • pituitary adenomas
  • molecular mechanisms
  • targeted therapies
  • immunotherapy
  • biomarkers
  • epigenetics

1. Introduction

Pituitary adenomas originate from the anterior pituitary gland and are generally slow-growing, benign neoplasms. They are classified based on size or cellular origin. The effective management of pituitary adenomas requires a multidisciplinary approach, incorporating both endocrinology and neurosurgery to achieve the best outcomes [1].
The updated classification system distinctly separates tumors of the anterior lobe (adenohypophyseal) from those of the posterior lobe (neurohypophyseal) and hypothalamic tumors, also including other neoplasms originating in the sellar region. Tumors of the anterior lobe are classified into (a) well-differentiated adenohypophyseal tumors, now referred to as pituitary neuroendocrine tumors (PitNETs, previously pituitary adenomas), (b) pituitary blastomas, and (c) two types of craniopharyngioma. This revised WHO classification emphasizes the histological subtyping of a PitNET, considering factors like tumor cell lineage, cell type, and associated characteristics. Routine immunohistochemistry for pituitary transcription factors (PIT1, TPIT, SF1, GATA3, and ERα) is crucial in this classification. The reclassification of all PitNETs/pituitary adenomas from a behavior code of “0” for benign tumors to “3” for primary malignant tumors is a subject of debate among experts [2][3].
Given the pituitary gland’s central position within the skull, pituitary tumors can exert pressure on vital brain structures as they enlarge. One common effect is the compression of optic nerves, leading to gradual vision loss, often beginning with peripheral vision. Furthermore, some pituitary adenomas may overproduce one or more hormones, resulting in hormonal imbalances that affect body functions, even when the tumors are small. Importantly, pituitary adenomas can occur in individuals of any age [4].

2. Epigenetics of Pituitary Adenomas

2.1. Introduction to the Role of Epigenetics in Tumor Development—Specific Changes Associated with Pituitary Adenomas

Epigenetic mechanisms are crucial in mammalian development and maintaining tissue-specific gene expression. Disruptions in these processes can lead to changes in gene functionality and malignant cellular transformation. Global epigenetic alterations are now recognized as a significant hallmark of cancer. Cancer, traditionally viewed as a genetic disorder, is increasingly understood to involve both genetic mutations and epigenetic anomalies [5]. Epigenetic phenomena such as nucleosome remodeling through histone modifications, DNA methylation, and microRNA (miRNA)-mediated gene targeting play critical roles in regulating biochemical pathways vital to tumorigenesis. Moreover, mutations in genes that regulate epigenetics have strengthened the connection between epigenetics and cancer [6].
Histone modifications in pituitary tumors have been linked to increased p53 expression and longer progression-free survival. Sirtuins, a class of proteins, have a higher expression in growth hormone-expressing adenomas than in nonfunctional ones and show an inverse correlation with tumor size in somatotrophs. The elevation of citrullinating enzymes has been proposed as an early marker in the pathogenesis of prolactinomas [7]. Epigenetic therapies targeting DNA methyltransferases (DNMTs) and histone deacetylases (HDACs) have been suggested to reactivate the expression of epigenetically silenced genes, potentially enhancing tumor cell sensitivity to conventional treatments like chemotherapy and radiotherapy [8].
miRNAs, small non-coding single-stranded RNAs that regulate gene expression post-transcriptionally, have been increasingly implicated in pituitary tumorigenesis. Variations in miRNA expression are linked with the development of pituitary tumors. Depending on the context, these miRNAs can act as oncosuppressors or oncogenes, underscoring their pivotal role in the onset and progression of these tumors [9][10][11].

2.2. Potential Therapeutic Avenues Targeting Epigenetic Modifications

The role of the histone deacetylase (HDAC) family, especially HDAC2 and HDAC3 from Class I, in the development of pituitary tumors is not fully understood. Studies have shown that HDAC2 and 3 are more highly expressed in clinically non-functioning pituitary adenomas compared to normal pituitary tissues, as evidenced by RT-PCR and immunohistochemical staining (IHC) analyses.
In a different research stream, LaPierre et al. explored the role of miR-7a2 in lactotrophic cell development and prolactin hormone synthesis, following preliminary data suggesting a connection between miR-7a2 deficiency and reduced prolactin expression. Contrary to initial expectations, they found that miR-7a2 knockout led to an early increase in lactotroph cell proliferation and prolactin production during embryonic development, but this was followed by a decrease in hormone production in adulthood. In contrast, the overexpression of miR-7a2 was linked to delayed lactotroph development. Further experiments in various mouse pituitary cell types and rat prolactinoma cells showed that miR-7a2 exerts its effects by inhibiting its target gene Raf1, a known promoter of prolactin production. This finding underscores the complex regulation of prolactin production. However, more research is necessary to fully elucidate miR-7a2’s role in hyperprolactinemia and evaluate its potential as a therapeutic target [9].

3. Transcriptomic Insights into Pituitary Adenomas

3.1. Overview of Transcriptomics and Its Significance in Cancer Biology

Transcriptome profiling has emerged as a crucial tool in oncology over recent decades, providing significant prognostic and predictive insights for cancer management. This approach has transformed cancer perception from a primarily histopathological and organ-centric perspective to a more molecularly based classification, enabling more personalized diagnostics and treatment strategies.
The development of single-cell transcriptomic sequencing represents a major leap in this area, offering a detailed analysis of tumor ecosystems and deepening the understanding of tumorigenesis at the cellular level [12][13][14]. Single-cell RNA sequencing (scRNA-seq) has been particularly influential in cancer cell research, uncovering new facets of cancer biology, including the cancer stem-cell concept, treatment resistance mechanisms, and the dynamics of cancer metastasis [14][15].
Analyses of altered transcriptional profiles in pituitary adenomas have revealed significant differences beyond genes involved in somatic copy number alterations (SCNAs). Tumors with disrupted genomes show more variability in gene expression compared to quieter tumors. This suggests that the processes leading to unstable genomes also result in diverse transcriptomes [16].
In prolactin-producing pituitary adenomas (PRL-PAs), research has identified widespread genomic copy number amplifications, which correlate with transcriptomic changes in this tumor subtype. High copy number variations (CNVs) in PRL-PA are associated with increased prolactin production, drug resistance, and proliferation, potentially through key genes like BCAT1. This research provides insights into the effects of genomic CNVs on transcriptomes and clinical outcomes in PRL-PA, highlighting potential therapeutic targets [17].
Pituitary adenomas have been categorized into three molecular clusters based on the transcription factor guiding their terminal differentiation. The first cluster, driven by NR5A1, includes clinically non-functioning pituitary adenomas, encompassing gonadotrophinomas and null cell adenomas. The second cluster, influenced by TBX19, contains clinically evident ACTH adenomas and silent corticotroph adenomas. The third cluster, driven by POU1F1, includes TSH-, PRL-, and GH-adenomas [18].

3.2. Implications for Targeted Therapy Based on Transcriptomic Data

Recent research has highlighted the importance of understanding the multiomic profiles of pituitary neuroendocrine tumors (PitNETs) to develop molecularly targeted therapies, especially for those resistant to current treatments. This aligns with the broader trend of applying precision medicine in cancer treatment [19].
In corticotrophinomas, a significant finding was the discovery of a somatic mutational hotspot in the ubiquitin-specific peptidase 8 (USP8) gene in nearly half of these tumors. This gene produces a protein that impedes the downregulation of the epidermal growth factor receptor (EGFR), leading to its prolonged activation. EGFR, crucial for corticotroph function, is highly expressed in Cushing’s pituitary tumors and stimulates ACTH synthesis. The mutation in corticotrophinomas increases USP8 activity, preventing EGFR degradation and maintaining its stimulatory effect [20][21].
In acromegaly treatment, the drug pasireotide has demonstrated greater efficacy than first-generation somatostatin analogs like octreotide or lanreotide, suggesting that it could become a new standard for patients who do not respond well to first-generation analogs [22].

4. Immunological Aspects of Pituitary Adenomas

4.1. Introduction to the Immune Response in Intracranial Tumors

An investigation into the immunological landscape of pituitary adenomas, using gene expression data, revealed a dominance of specific immune cell types. The most prevalent infiltrating immune cells in these tumors are M2 macrophages, followed by resting CD4+ memory T cells and mast cells. Silent pituitary tumors particularly show a higher fraction of M2 macrophages compared to other subtypes. Conversely, Cushing’s pituitary tumors, including overt and subclinical cases, have a higher proportion of CD8+ T cells than growth hormone (GH) tumors, prolactinomas, hyperthyroid tumors, and silent tumors [23].
The tumor microenvironment immune composition (TMIC) in pituitary adenomas consists of myeloid cells like tumor-associated macrophages, dendritic cells, and lymphocytes including T cells and B cells (Figure 1). The interplay between these infiltrating immune cells, their secretions, the tumor, and its host is intricate, and it can lead to either tumor-promoting or anti-tumor effects [24].
Biomedicines 12 00023 g001
Figure 1. Infiltration of immune cells into PAs and their potential in the invasion, migration, and proliferation of PAs.

4.2. Opportunities and Challenges for Immunotherapy in Pituitary Adenomas

The tumor immune microenvironment (TIM) plays a crucial role in cancer prognosis and the effectiveness of immunotherapies [25]. In pituitary adenomas, T cells have been identified as the predominant immune cells across various subtypes. A relationship between tumor size, patient age, and the density of tumor-infiltrating immune cells (TIICs) has been established. Particularly in corticotroph adenomas with USP8 mutations, a significant impact on the distribution of TIICs has been noted. PAs have been classified into three immune clusters based on TIIC distributions, each with distinct immune checkpoint molecule (ICM) expression patterns, correlating with different tumor evolution and progression pathways. Cluster 1 exhibits increased CTLA4/CD86 expression, while cluster 2 is marked by elevated programmed cell death protein 1/programmed cell death 1 ligand 2 (PD1/PD-L2) expression [25].
The expression of HSPB1 is significantly higher in most tumors compared to normal tissues. High levels of HSPB1 have been associated with reduced overall survival, indicating its role in immune system regulation within various cancers. Compounds like DB11638, DB06094, and DB12695 are being investigated as HSPB1 inhibitors, underscoring its potential as a therapeutic target in invasive pituitary adenoma. Thus, HSPB1 could serve as an important biomarker, influencing tumor progression through its impact on the immune system [26].

5. The Tumor Microenvironment in Pituitary Adenomas

5.1. Exploring the Microenvironment’s Contribution to Pituitary Adenoma Progression

In the tumor microenvironment, the presence and activity of non-tumoral cells significantly affect tumor proliferation, invasiveness, and angiogenesis.
Fibroblasts, usually in a dormant mesenchymal state, can become activated in response to various stimuli, contributing to both normal physiological processes like wound healing and pathological processes such as tumor progression. Tumor-associated fibroblasts (TAFs) are abnormally activated due to growth factors and cytokines produced by cancer cells [27]. These activated TAFs secrete a variety of molecules that are key in remodeling the extracellular matrix and facilitating tumor growth, invasiveness, metastasis, and resistance to treatment [28][29].
Interleukin-6 (IL-6) plays a role in hormone release, tumor growth and proliferation, and the production of angiogenic factors, particularly vascular endothelial growth factor-A (VEGF-A) [30]. It has been found that IL-6 stimulates the growth of GH3 rat pituitary tumor cells while inhibiting the growth of normal rat pituitary cells. IL-6 can reach the pituitary through systemic circulation and is also produced within the pituitary, having paracrine effects.

5.2. Strategies to Target and Modulate the Tumor Microenvironment for Therapeutic Advantage

The enhanced understanding of the immune tumor microenvironment (TME) has been pivotal in the development and clinical implementation of immuno-checkpoint inhibitors (ICIs), significantly transforming the treatment of various cancers in the past decade [31]. In light of these developments, ICIs are being explored as a new therapeutic option for aggressive pituitary adenomas/PitNETs and in the rarer instances of pituitary carcinomas [24].
Tumor-associated fibroblasts (TAFs) within the TME of pituitary adenomas play a crucial biological role. Cytokines released from TAFs can impact both tumoral and non-tumoral cells, including macrophages. This interaction may enhance tumor invasiveness and influence angiogenesis and epithelial-to-mesenchymal pathways in PAs. IL-6 and CCL2 have been identified as key factors in this process. Intriguingly, the somatostatin analogue pasireotide has been found to inhibit the secretions of TAFs, suggesting a potential anti-tumoral effect of somatostatin analogues (SSAs) by directly targeting TAFs and thus altering the TME in PAs [32] (Figure 2).
Biomedicines 12 00023 g002
Figure 2. Microenvironmental influence on pituitary tumor dynamics. An examination of the pituitary tumor microenvironment’s composition and its profound influence on tumor behavior, with specific emphasis on critical tumorigenic processes such as tumor cell proliferation, invasion, tumor initiation, angiogenesis, the activation of the epithelial-to-mesenchymal transition pathway, the modulation of the microenvironment, and responsiveness to therapeutic interventions. Abbreviations: Pt = pituitary tumors; TME = tumor microenvironment; TAM = tumor-associated macrophages; TAF = tumor-associated fibroblasts; TIL = tumor-infiltrating lymphocytes; AIP = aryl hydrocarbon receptor-interacting protein; CSF-1 = colony-stimulating factor 1.

6. Biomarkers: The Future of Diagnosis and Treatment

6.1. The Importance of Biomarkers in Oncology

In oncology, biomarkers play a multifaceted and essential role, spanning risk assessment, screening, differential diagnosis, prognosis, the prediction of response to treatment, and monitoring cancer progression. The rapid advancement in technology has spurred extensive research into a wide array of potential biomarkers, leading to significant developments in this field [33]. These biomarkers are varied, encompassing different biochemical forms such as nucleic acids, proteins, carbohydrates, lipids, small metabolic products, cytogenetic and cytokinetic indicators, and entire tumor cells in bodily fluids [34].
The search for biomarkers that can predict response to immunotherapy is an active and growing area of research. A deeper understanding of immune system dynamics is anticipated to enhance the efficacy of immunotherapy, allowing for treatments to be tailored to the specific needs of individual patients. Central to this effort is the development and improvement of analytical platforms and assays for accurate and consistent biomarker quantification both within and between individuals [35].

6.2. Exploring Potential Biomarkers Specific to Intracranial Tumors and Pituitary Adenomas

Several biomarkers have been identified that possess predictive value for managing pituitary tumors, particularly concerning their clinical and radiological characteristics.
The cell cycle is regulated by key components such as cyclins, cyclin-dependent kinases (CDKs), and their inhibitors (CDKIs). There are two main families of CDKIs: the INK family (including INK4a/p16, INK4b/p15, INK4c/p18, and INK4d/p19) and the WAF/KIP family (comprising WAF1/p21, KIP1/p27, and KIP2/p57). The progression through the cell cycle is largely controlled by fluctuations in the levels of cyclins and CDKIs, which are regulated via programmed degradation by the ubiquitin–proteasome system [36].
In adrenocorticotrophic hormone-secreting pituitary tumors, the roles of matrix metalloproteinase-9 (MMP-9), pituitary tumor-transforming gene (PTTG), and high mobility group A 2 (HMGA2) in tumor development are well established. However, their relationships with tumor recurrence following transsphenoidal adenomectomy remain unclear.
Vascular endothelial growth factor plays a vital role in angiogenesis, a process critical in both developmental stages and pathological conditions in pituitary tumors. A significant amount of preclinical and clinical research has highlighted the importance of anti-VEGF therapy in treating pituitary tumors [37][38].

6.3. Role of Biomarkers in Early Diagnosis and Targeted Therapies

Pituitary adenomas exhibit varied behaviors, and predicting their potential for aggressive or malignant transformation is complex. Biomarkers are increasingly recognized as vital in this context, including a range of factors such as chromosomal changes, microRNAs, markers of cellular proliferation, oncogenes, tumor suppressor genes, growth factors and their receptors, and elements related to angiogenesis or cell adhesion [39].
Recent research has identified three RNA subtypes, messenger-RNA, long non-coding RNA, and micro-RNA, that show correlations with PitNETs. However, their exploration in liquid biopsies remains limited, with only a few studies conducted so far.

7. Old and Emerging Targets for Therapy

7.1. Historical Treatment Options: A Static Landscape

7.1.1. Analysis of Traditional Treatments over the Past 20 Years

In the past two decades, there has been significant progress in the treatment approaches for intracranial tumors. Radiation therapy, traditionally key in treating malignant and aggressive intracranial tumors, has proven its effectiveness by extending patient survival rates and improving tumor control.
Radiotherapy (RT) is a core element in the management of malignant tumors and is increasingly being applied to benign conditions. The effectiveness of low to intermediate doses of RT has been extensively studied. However, the application of post-operative radiotherapy (PORT) continues to be debated, in spite of numerous trials and meta-analyses conducted over many years [40].
The execution of large-scale, multicenter therapeutic trials remains a challenge. Future research is expected to increasingly depend on data from translational clinical trials, particularly those using canine intracranial tumor models. Continuous data collection and analysis regarding the natural biology and clinical progression of specific tumor types and grades are crucial for evaluating therapeutic methods. This requires a minimum histologic diagnosis for publication.

7.1.2. The Exceptions: Pituitary Adenomas and the Alternative Treatments

Pituitary adenomas constitute around 15% of all brain tumors, and their detection is increasingly common, largely due to the widespread use of magnetic resonance imaging. Surgical intervention is the primary treatment for most of these tumors. The effectiveness of dopaminergic agonists and somatostatin receptor ligands (SRLs) in treating specific types of pituitary adenomas, notably prolactinomas and growth hormone excess, is well established. Over the past decade, there has been an increase in the application of new multi-receptor binding SRLs for acromegaly and Cushing’s disease treatment [41].
Functional pituitary adenomas, which can cause morbidity through hormone hypersecretion, are often effectively managed with medical therapies aimed at inhibiting pituitary hormone secretion or the response of target organs. These medical interventions are non-invasive and mitigate the anatomical and potentially permanent risks associated with surgical and radiation treatments. However, aside from prolactinomas, typically medical therapies are not curative and are unlikely to fully eliminate the adenoma. The main objective of these therapies is to attain biochemical control, and treatment risks vary based on the specific medication. Considering that these therapies might be prolonged or indefinite, understanding patient tolerability is essential [4].
Radiotherapy has been proven effective in managing pituitary adenomas, achieving 97.9% radiological control and 93.6% biochemical control over a median six-year follow-up period post radiotherapy [42]. Techniques like intensity-modulated radiation therapy, stereotactic radiosurgery, and proton beam radiation therapy, which focus energy beams precisely on the tumor to minimize damage to adjacent healthy tissues, are employed [43].

7.2. Targeted Therapies

Pituitary adenomas are linked with several related disorders, including prolactinoma, acromegaly, Cushing’s disease, and non-functioning pituitary adenoma. Treatment often requires a combination of surgery, medical therapies (such as dopamine agonists or somatostatin receptor ligands), and radiotherapy, due to their significant impact on patient mortality, morbidity, and quality of life [44][45]. Transsphenoidal surgery is usually the first-line treatment for pituitary tumors, except for prolactinomas. However, the tumor’s local invasiveness may complicate surgical resection, occasionally necessitating initial medical therapy [46].

Prolactinomas, the most common type of secretory pituitary tumors, can cause symptoms from prolactin oversecretion, localized mass effects, or both [47]. Traditionally, dopamine agonists have been the primary treatment, with cabergoline effectively normalizing prolactin levels in most patients and inducing tumor shrinkage in many. The surgical resection of microprolactinomas and encapsulated macroprolactinomas can achieve remission rates similar to cabergoline treatment [48].
Acromegaly, a chronic disease caused mainly by growth hormone-secreting PitNETs, can lead to severe health issues and increased mortality if not properly managed. Transsphenoidal surgery is preferred for GH-secreting PitNETs, with medical therapy, especially long-acting somatostatin analogs, used when surgery is not possible or incomplete, achieving control in about half of the patients [49].
Cushing’s disease, caused by an ACTH-secreting pituitary tumor, is the most common form of Cushing’s syndrome and requires prompt diagnosis and treatment to improve outcomes [50]. Surgery is the initial therapy, but when it is not curative, medical therapy becomes a significant secondary option. New drugs and formulations are being investigated for their efficacy and safety in treating Cushing’s disease [51].
Non-functioning pituitary adenomas, benign tumors that do not cause hormonal hypersecretion, are primarily treated with surgery, but recurrence rates are high [52]. Post surgery, dopamine agonists have been explored to prevent recurrence, showing some initial promise but diminishing effectiveness over time. The role of medical therapy in preventing NFPA regrowth remains limited [53].
In managing pituitary adenomas, including prolactinoma, acromegaly, Cushing’s disease, and non-functioning pituitary adenoma, transsphenoidal surgery is typically the primary treatment, except for prolactinomas. Sometimes, the tumor’s invasiveness may necessitate initial medical intervention.
Surgical resection maintains its status as a core strategy in managing brain tumors (BM), with its effectiveness in BM surgery being well established. A critical aspect of surgical intervention is the method employed, wherein en bloc resection, the removal of the tumor in a single piece, has been shown to offer better local control compared to piecemeal tumor resection. This approach also involves the minimal removal of adjacent normal brain tissue [54]. En bloc resection is notable for its potential to decrease intraoperative tumor spread relative to piecemeal resection. Patel et al. observed that en bloc resection does not correlate with an increase in complications or adverse functional outcomes [55].
Most pituitary adenomas can be effectively managed with current medical treatments, surgical interventions, and, in some cases, radiotherapy. However, gonadotroph adenomas are particularly challenging due to the lack of effective medical treatments.
For prolactinomas, the use of dopamine agonists has been a primary treatment strategy since the 1970s. The initial use of bromocriptine later shifted to cabergoline, which has been effective in regulating prolactin levels in up to 85% of patients and reducing tumor size in about 80% of cases. The surgical removal of both microprolactinomas and larger macroprolactinomas, when performed by neurosurgeons specialized in pituitary disorders, has achieved remission rates comparable to those obtained with cabergoline therapy. For particularly aggressive prolactinomas and metastasized PitNETs, a comprehensive treatment approach is recommended. This includes higher doses of cabergoline, surgical intervention, radiation therapy (preferably stereotactic radiosurgery when possible), and temozolomide administration. While DAs remain effective for most prolactinoma cases, the success rates of transsphenoidal surgical methods have significantly improved recently, especially with the expertise of specialized surgeons [56].

7.3. Potential Novel Targets

Innovative targeted therapies for pituitary tumor treatment are focusing on inhibitors of the mammalian target of rapamycin (mTOR), tyrosine kinase, and vascular endothelial growth factor. Advances in the molecular characterization of endocrine tumors through genomic, epigenomic, and transcriptomic analyses have provided a more in-depth understanding of their pathogenesis and molecular pathology. This has led to an increased application of molecular targeted therapies (MTTs) in patient care [57]. The mTOR protein kinase is vital for regulating various cellular processes, including metabolism, catabolism, immune responses, autophagy, survival, proliferation, and migration, thus maintaining cellular homeostasis.
Immune checkpoint treatment represents a very promising therapeutic avenue for neoplasms [58][59][60]. This therapeutic avenue is also a very hopeful option for pituitary adenomas. There is a well-established correlation between mismatch repair deficiency (MMRd) and the heightened responsiveness to anti-PD-1 therapies in various malignancies. This association can be effectively identified through the immunohistochemical analysis of markers such as MLH1, MSH2, MHS6, and PMS2. An instance of accelerated disease progression was reported in the literature following the administration of pembrolizumab in a patient diagnosed with an MMRd pituitary ACTH-secreting adenoma, showcasing the limited efficacy observed with pembrolizumab in the treatment of an ACTH-secreting pituitary adenoma characterized by mismatch repair deficiency, potentially attributable to elevated cortisol levels in the patient [61]. 

This entry is adapted from the peer-reviewed paper 10.3390/biomedicines12010023

References

  1. Rutenberg, M.S.; Rotondo, R.L.; Rao, D.; Holtzman, A.L.; Indelicato, D.J.; Huh, S.; Morris, C.G.; Mendenhall, W.M. Clinical outcomes following proton therapy for adult craniopharyngioma: A single-institution cohort study. J. Neurooncol. 2020, 147, 387–395.
  2. Asa, S.L.; Mete, O.; Perry, A.; Osamura, R.Y. Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr. Pathol. 2022, 33, 6–26.
  3. Vergeer, R.A.; Postma, M.R.; Schmidt, I.; Korsten-Meijer, A.G.; Feijen, R.A.; Kruijff, S.; Nagengast, W.B.; van Dijk, J.M.C.; Dunnen, W.F.A.D.; van Beek, A.P.; et al. Detection by fluorescence of pituitary neuroendocrine tumour (PitNET) tissue during endoscopic transsphenoidal surgery using bevacizumab-800CW (DEPARTURE trial): Study protocol for a non-randomised, non-blinded, single centre, feasibility and dose-finding trial. BMJ Open 2021, 11, e049109.
  4. Guo, X.; Zhang, D.; Pang, H.; Wang, Z.; Gao, L.; Wang, Y.; Ma, W.; Lian, W.; Xing, B. Safety of Withholding Perioperative Hydrocortisone for Patients with Pituitary Adenomas with an Intact Hypothalamus-Pituitary-Adrenal Axis: A Randomized Clinical Trial. JAMA Netw. Open 2022, 5, e2242221.
  5. Sharma, S.; Kelly, T.K.; Jones, P.A. Epigenetics in cancer. Carcinogenesis 2010, 31, 27–36.
  6. Liu, A.P.Y.; Gudenas, B.; Lin, T.; Orr, B.A.; Klimo, P.; Kumar, R.; Bouffet, E.; Gururangan, S.; Crawford, J.R.; Kellie, S.J.; et al. Risk-adapted therapy and biological heterogeneity in pineoblastoma: Integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. Acta Neuropathol. 2020, 139, 259–271.
  7. Hauser, B.M.; Lau, A.; Gupta, S.; Bi, W.L.; Dunn, I.F. The Epigenomics of Pituitary Adenoma. Front. Endocrinol. 2019, 10, 290.
  8. Fuks, F.; Burgers, W.A.; Brehm, A.; Hughes-Davies, L.; Kouzarides, T. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat. Genet. 2000, 24, 88–91.
  9. LaPierre, M.P.; Godbersen, S.; Esteban, M.T.; Schad, A.N.; Treier, M.; Ghoshdastider, U.; Stoffel, M. MicroRNA-7a2 Regulates Prolactin in Developing Lactotrophs and Prolactinoma Cells. Endocrinology 2021, 162, bqaa220.
  10. Armagan, D.M.; Akdemir, A.S.; Ozkaya, H.M.; Korkmaz, O.P.; Gazioglu, N.; Kadioglu, P.; Tanriover, N.; Dagistanli, K.-F.; Dirican, A.; Ozturk, M. SNPs of miR-23b, miR-107 and HMGA2 and their Relations with the Response to Medical Treatment in Acromegaly Patients. Exp. Clin. Endocrinol. Diabetes 2021, 129, 593–600.
  11. Zhao, P.; Cheng, J.; Li, B.; Nie, D.; Li, C.; Gui, S.; Wang, H.; Zhang, Y. Up-regulation of the expressions of MiR-149-5p and MiR-99a-3p in exosome inhibits the progress of pituitary adenomas. Cell Biol. Toxicol. 2021, 37, 633–651.
  12. Bi, K.; He, M.X.; Bakouny, Z.; Kanodia, A.; Napolitano, S.; Wu, J.; Grimaldi, G.; Braun, D.A.; Cuoco, M.S.; Mayorga, A.; et al. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell 2021, 39, 649–661.e5.
  13. Velten, L.; Story, B.A.; Hernández-Malmierca, P.; Raffel, S.; Leonce, D.R.; Milbank, J.; Paulsen, M.; Demir, A.; Szu-Tu, C.; Frömel, R.; et al. Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics. Nat. Commun. 2021, 12, 1366.
  14. Xing, X.; Yang, F.; Huang, Q.; Guo, H.; Li, J.; Qiu, M.; Bai, F.; Wang, J. Decoding the multicellular ecosystem of lung adenocarcinoma manifested as pulmonary subsolid nodules by single-cell RNA sequencing. Sci. Adv. 2021, 7, eabd9738.
  15. Zhang, L.; Zhang, Z. Recharacterizing Tumor-Infiltrating Lymphocytes by Single-Cell RNA Sequencing. Cancer Immunol. Res. 2019, 7, 1040–1046.
  16. Bi, W.L.; Horowitz, P.; Greenwald, N.F.; Abedalthagafi, M.; Agarwalla, P.K.; Gibson, W.J.; Mei, Y.; Schumacher, S.E.; Ben-David, U.; Chevalier, A.; et al. Landscape of genomic alterations in pituitary adenomas. Clin. Cancer Res. 2017, 23, 1841–1851.
  17. Chen, Y.; Gao, H.; Xie, W.; Guo, J.; Fang, Q.; Zhao, P.; Liu, C.; Zhu, H.; Wang, Z.; Wang, J.; et al. Genomic and transcriptomic analysis of pituitary adenomas reveals the impacts of copy number variations on gene expression and clinical prognosis among prolactin-secreting subtype. Aging 2020, 13, 1276–1293.
  18. Taniguchi-Ponciano, K.; Andonegui-Elguera, S.; Peña-Martínez, E.; Silva-Román, G.; Vela-Patiño, S.; Gomez-Apo, E.; Chavez-Macias, L.; Vargas-Ortega, G.; Espinosa-De-Los-Monteros, L.; Gonzalez-Virla, B.; et al. Transcriptome and methylome analysis reveals three cellular origins of pituitary tumors. Sci. Rep. 2020, 10, 19373.
  19. Oh, J.Y.; Osorio, R.C.; Jung, J.; Carrete, L.; Choudhary, N.; Lad, M.; Saha, A.; Aghi, M.K. Transcriptomic Profiles of Normal Pituitary Cells and Pituitary Neuroendocrine Tumor Cells. Cancers 2022, 15, 110.
  20. Boyle, J.; Patronas, N.J.; Smirniotopoulos, J.; Herscovitch, P.; Dieckman, W.; Millo, C.; Maric, D.; Chatain, G.P.; Hayes, C.P.; Benzo, S.; et al. CRH stimulation improves 18F-FDG-PET detection of pituitary adenomas in Cushing’s disease. Endocrine 2019, 65, 155–165.
  21. Xiao, D.; Hu, X.; Peng, M.; Deng, J.; Zhou, S.; Xu, S.; Wu, J.; Yang, X. Inhibitory role of proguanil on the growth of bladder cancer via enhancing EGFR degradation and inhibiting its downstream signaling pathway to induce autophagy. Cell Death Dis. 2022, 13, 499.
  22. Gadelha, M.R.; Bronstein, M.D.; Brue, T.; Coculescu, M.; Fleseriu, M.; Guitelman, M.; Pronin, V.; Raverot, G.; Shimon, I.; Lievre, K.K.; et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): A randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014, 2, 875–884.
  23. Yeung, J.T.; Vesely, M.D.; Miyagishima, D.F. In silico analysis of the immunological landscape of pituitary adenomas. J. Neurooncol. 2020, 147, 595–598.
  24. Ilie, M.D.; Vasiljevic, A.; Raverot, G.; Bertolino, P. The Microenvironment of Pituitary Tumors—Biological and Therapeutic Implications. Cancers 2019, 11, 1605.
  25. Wang, Z.; Guo, X.; Gao, L.; Deng, K.; Lian, W.; Bao, X.; Feng, M.; Duan, L.; Zhu, H.; Xing, B. The Immune Profile of Pituitary Adenomas and a Novel Immune Classification for Predicting Immunotherapy Responsiveness. J. Clin. Endocrinol. Metab. 2020, 105, e3207–e3223.
  26. Zhao, S.; Li, B.; Chen, Y.; Li, C.; Zhang, Y. Analysis of the Prognostic and Immunological Role of HSPB1 in Pituitary Adenoma: A Potential Target for Therapy. Medicina 2023, 59, 885.
  27. Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 2016, 16, 582–598.
  28. Luga, V.; Wrana, J.L. Tumor–Stroma Interaction: Revealing Fibroblast-Secreted Exosomes as Potent Regulators of Wnt-Planar Cell Polarity Signaling in Cancer Metastasis. Cancer Res. 2013, 73, 6843–6847.
  29. Paraiso, K.H.T.; Smalley, K.S.M. Fibroblast-mediated drug resistance in cancer. Biochem. Pharmacol. 2013, 85, 1033–1041.
  30. Sapochnik, M.; Fuertes, M.; Arzt, E. Programmed cell senescence: Role of IL-6 in the pituitary. J. Mol. Endocrinol. 2017, 58, R241–R253.
  31. Chiloiro, S.; Capoluongo, E.D.; Tartaglione, T.; Giampietro, A.; Bianchi, A.; Giustina, A.; Pontecorvi, A.; De Marinis, L. The Changing Clinical Spectrum of Hypophysitis. Trends Endocrinol. Metab. 2019, 30, 590–602.
  32. Marques, P.; Barry, S.; Carlsen, E.; Collier, D.; Ronaldson, A.; Awad, S.; Dorward, N.; Grieve, J.; Balkwill, F.; Korbonits, M. MON-460 Pasireotide Treatment Inhibits Cytokine Release from Pituitary Adenoma-Associated Fibroblasts: Is This Mechanism Playing a Key Role in Its Effect? J. Endocr. Soc. 2019, 3 (Suppl. S1), MON-460.
  33. Bodaghi, A.; Fattahi, N.; Ramazani, A. Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of COVID-19 and other diseases. Heliyon 2023, 9, e13323.
  34. Bhatt, A.N.; Mathur, R.; Farooque, A.; Verma, A.; Dwarakanath, B.S. Cancer biomarkers—Current perspectives. Indian J. Med. Res. 2010, 132, 129–149.
  35. Nixon, A.B.; Schalper, K.A.; Jacobs, I.; Potluri, S.; Wang, I.-M.; Fleener, C. Peripheral immune-based biomarkers in cancer immunotherapy: Can we realize their predictive potential? J. Immunother. Cancer 2019, 7, 325.
  36. Hurvitz, S.A.; Martin, M.; Press, M.F.; Chan, D.; Fernandez-Abad, M.; Petru, E.; Rostorfer, R.; Guarneri, V.; Huang, C.-S.; Barriga, S.; et al. Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer. Clin. Cancer Res. 2020, 26, 566–580.
  37. Lamb, L.S.; Sim, H.-W.; McCormack, A.I. Case Report: A Case of Pituitary Carcinoma Treated with Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy. Front. Endocrinol. 2020, 11, 576027.
  38. Xu, L.; Khaddour, K.; Chen, J.; Rich, K.M.; Perrin, R.J.; Campian, J.L. Pituitary carcinoma: Two case reports and review of literature. World J. Clin. Oncol. 2020, 11, 91–102.
  39. Pan, Q.; Chegini, N. MicroRNA Signature and Regulatory Functions in the Endometrium during Normal and Disease States. Semin. Reprod. Med. 2008, 26, 479–493.
  40. Paumier, A.; Le Péchoux, C. Post-operative radiation therapy. Transl. Lung Cancer Res. 2013, 2, 423–432.
  41. Mondin, A.; Manara, R.; Voltan, G.; Tizianel, I.; Denaro, L.; Ferrari, M.; Barbot, M.; Scaroni, C.; Ceccato, F. Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis. Front. Endocrinol. 2022, 13, 935759.
  42. Sebastian, P.; Balakrishnan, R.; Yadav, B.; John, S. Outcome of radiotherapy for pituitary adenomas. Rep. Pract. Oncol. Radiother. 2016, 21, 466–472.
  43. Sundlöv, A.; Sjögreen-Gleisner, K.; Tennvall, J.; Dahl, L.; Svensson, J.; Åkesson, A.; Bernhardt, P.; Lindgren, O. Pituitary Function after High-Dose 177Lu-DOTATATE Therapy and Long-Term Follow-Up. Neuroendocrinology 2021, 111, 344–353.
  44. Melmed, S. Pituitary-Tumor Endocrinopathies. N. Engl. J. Med. 2020, 382, 937–950.
  45. Brue, T.; Castinetti, F. The risks of overlooking the diagnosis of secreting pituitary adenomas. Orphanet J. Rare Dis. 2016, 11, 135.
  46. Molitch, M.E. Diagnosis and Treatment of Pituitary Adenomas: A. Review. JAMA 2017, 317, 516–524.
  47. Barbosa, F.R.P.; Silva, C.M.d.S.; Lima, G.A.B.; Warszawski, L.; Domingues, R.C.; Dominic, M.; Fontes, R.; Neto, L.V.; Gadelha, M.R. Prevalence of obstructive sleep apnea in patients with prolactinoma before and after treatment with dopamine agonists. Pituitary 2014, 17, 441–449.
  48. Searle, L.; McDowell, S.; Willink, R.; Krebs, J. A cannulated prolactin series reduces the need for further investigations in women with infertility and lowers the number of false positive screening prolactin measurements. Aust. N. Z. J. Obstet. Gynaecol. 2021, 61, 949–954.
  49. Petersenn, S.; Houchard, A.; Sert, C.; Caron, P.J. PRIMARYS Study Group, Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: Post hoc analyses from the PRIMARYS study. Pituitary 2020, 23, 171–181.
  50. Walia, R.; Gupta, R.; Bhansali, A.; Pivonello, R.; Kumar, R.; Singh, H.; Ahuja, C.; Chhabra, R.; Singh, A.; Dhandapani, S.; et al. Molecular Imaging Targeting Corticotropin-releasing Hormone Receptor for Corticotropinoma: A Changing Paradigm. J. Clin. Endocrinol. Metab. 2021, 106, e1816–e1826.
  51. Graffeo, C.S.; Carlstrom, L.P.; Cohen, S.C.; Perry, A.; Choby, G.; Van Gompel, J.J. Perioperative Tranexamic Acid for ACTH-Secreting Pituitary Adenomas: Implementation Protocol Results and Trial Prospectus. World Neurosurg. 2021, 153, e359–e364.
  52. Batista, R.L.; Musolino, N.R.; Cescato, V.A.; da Silva, G.O.; Medeiros, R.S.; Herkenhoff, C.G.; Trarbach, E.B.; Cunha-Neto, M.B. Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma: A Single-Center, Open-Label, 2-Year Randomized Clinical Trial. Am. J. Clin. Oncol. 2019, 42, 221–227.
  53. Yu, S.; Wang, X.-S.; Cao, K.-C.; Bao, X.-J.; Yu, J. Identification of CDK6 and RHOU in Serum Exosome as Biomarkers for the Invasiveness of Non-functioning Pituitary Adenoma. Chin. Med. Sci. J. 2019, 34, 168–176.
  54. Patel, A.J.; Suki, D.; Hatiboglu, M.A.; Abouassi, H.; Shi, W.; Wildrick, D.M.; Lang, F.F.; Sawaya, R. Factors influencing the risk of local recurrence after resection of a single brain metastasis. J. Neurosurg. 2010, 113, 181–189.
  55. Patel, A.J.; Suki, D.; Hatiboglu, M.A.; Rao, V.Y.; Fox, B.D.; Sawaya, R. Impact of surgical methodology on the complication rate and functional outcome of patients with a single brain metastasis. J. Neurosurg. 2015, 122, 1132–1143.
  56. Burman, P.; Casar-Borota, O.; Perez-Rivas, L.G.; Dekkers, O.M. Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment. J. Clin. Endocrinol. Metab. 2023, 108, 1585–1601.
  57. Wang, S.; Lu, J.; You, Q.; Huang, H.; Chen, Y.; Liu, K. The mTOR/AP-1/VEGF signaling pathway regulates vascular endothelial cell growth. Oncotarget 2016, 7, 53269–53276.
  58. Korman, A.J.; Garrett-Thomson, S.C.; Lonberg, N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat. Rev. Drug Discov. 2022, 21, 509–528.
  59. Klein, S.; Persa, O.-D.; Mauch, C.; Noh, K.-W.; Pappesch, R.; Wagener-Ryczek, S.; Buettner, R.; Quaas, A.; Helbig, D. First report on two cases of pleomorphic dermal sarcoma successfully treated with immune checkpoint inhibitors. OncoImmunology 2019, 8, e1665977.
  60. Li, X.; Wang, Y.; Li, X.; Feng, G.; Hu, S.; Bai, Y. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC. Front. Immunol. 2021, 12, 638763.
  61. Caccese, M.; Barbot, M.; Ceccato, F.; Padovan, M.; Gardiman, M.P.; Fassan, M.; Denaro, L.; Emanuelli, E.; D’avella, D.; Scaroni, C.; et al. Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab. Anticancer Drugs 2020, 31, 199–204.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Video Production Service
Feedback